BeOne Medicines (BeiGene)ONC
Recorded

BeOne Medicines (BeiGene) Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration27 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Faisal KhurshidSenior Biotech Analyst

Good morning, everyone. Thank you for joining us. My name is Faisal Khurshid. I am one of the senior biotech analysts at Jefferies. We are here in London at the Jefferies Global Healthcare Conference. Really pleased to have with us today management team of BeOne Medicines. I have on stage with me Aaron Rosenberg and Mark Lanasa. Aaron, can I pass it off to you for a quick introduction? Then we got a ton of topics to get into.

Aaron RosenbergCFO

Sure. I am Aaron Rosenberg, the CFO of the company, along with Mark Lanasa, our solid tumor chief medical officer. Not marketing. Yeah. We are thrilled to be here.

Aaron RosenbergCFO

Look forward to a great discussion about the business.

Faisal KhurshidSenior Biotech Analyst

Got it. Awesome. It is really great to have Dr. Lanasa here. Mark, can you just give us like a quick background on your role? I think that will provide context for really what we are going to spend most of the time talking about.

Mark LanasaChief Medical Officer for Solid Tumors

Sure. As you heard, my role is I am the Chief Medical Officer for solid tumors at BeOne. I have been here for almost five years now. I am a medical oncologist by training. My role is to oversee the end-to-end development of our growing solid tumor portfolio. It has been a really exciting year with multiple important data readouts. We have intentionally substantially grown our portfolio from having a, shall we say, predominant focus on immuno-oncology to having a much broader and more diversified portfolio of targeted therapies across lung, GI, and breast cancers.

Faisal KhurshidSenior Biotech Analyst

Got it. Aaron, I would say, I mean, 2026, I think, has really felt like the year where the solid tumor portfolio has really come to life, with several programs moving into late stage. Mark, we are going to get into some of the science, some of the data, but before we get there, Aaron, can I just ask you to talk a little bit about, as you think about the evolution of BeOne Medicines, the kind of importance of the solid tumor franchise to the kind of long-term journey here?

Aaron RosenbergCFO

Absolutely. The business has really been performing across the value chain. The company has gone through a series of inflection points in just the short time since I have been here. I joined in July 2024. Moving from a business with high growth, but shifting towards profit generation, establishing itself with its leading hematology franchise, BRUKINSA, solidifying its position as the leading BTKI in the class, generating more than $1 billion of revenue in the U.S. alone in Q3, $1.4 billion globally. The continued advancement of our hematology pipeline, BEQALZI, our next-generation BCL2 inhibitor, which is now approved for relapse refractory MCL in the U.S., as well as relapse refractory CLL in China. The advancement of our BTK degrader, which we talked about at our Q3 results, which met its objectives of its phase II trial, which could support potential accelerated submission mid-2027.

Aaron RosenbergCFO

This year was certainly another inflection point as our solid tumor pipeline, we really focused on five key assets, but really, that is just the first wave of assets that we put into the clinic over the last two years, that all five assets we have read out really strong data sets at ASCO with our CDK4 and our B7-H4 ADC, with our PRMT5, GPC3, and our CEA ADC. All of those assets are moving, if not already started, in pivotal trials, but they are all moving toward those and have read out really significant data sets. This is another inflection point for the business, and we advance from a leading BTKI to a hematology franchise, and now, what is incredibly important, a multi-franchise oncology leading position. We are really excited about how the pipeline is shaping up.

Faisal KhurshidSenior Biotech Analyst

Got it. Mark, can I put you on the spot, for these five kind of assets that you guys have profiled, that you've had data for this year, that you're moving into late-stage development, can I ask you to kind of like force rank, talk about your sort of level of excitement across the five?

Mark LanasaChief Medical Officer for Solid Tumors

Sure. We have excitement and belief in all five molecules, which is why we're taking them into pivotal study, but I appreciate the question.

Faisal KhurshidSenior Biotech Analyst

Yes, sir. I know it's the pick your favorite kid question.

Mark LanasaChief Medical Officer for Solid Tumors

Yeah. No, no. I- Make him answer it.

Mark LanasaChief Medical Officer for Solid Tumors

Yes. No, happy to do so. I will start with our GPC3 x 4-1BB, which is, in our belief, a first-in-class molecule for hepatocellular carcinoma, which has been a relatively neglected space. We have increasing confidence that this can be a transformational molecule for patients with liver cancer, which is not a rare disease. There are greater than 30,000 new cases a year in the U.S. It is the sixth leading cause of cancer mortality in the U.S. So, substantial unmet medical need. We just presented data at ESMO that our molecule as monotherapy at later line has a response rate of 35% confirmed response rate. This is with strong durability, greater than 70% six-month duration of response rate.

Mark LanasaChief Medical Officer for Solid Tumors

This compares very favorably to current standard of care, where the response rate is expected to be only about 5% with tyrosine kinase inhibitors, and has a very much favorable safety profile compared to the multi-targeted TKIs. From there, I would highlight our MTA cooperative PRMT5. Again, we just shared data at the ESMO Congress. It was a first disclosure, but a substantial disclosure. Our molecule is the most potent and selective inhibitor of PRMT5 that is under clinical investigation, based on our internal studies. Critically, our molecule was designed to be CNS penetrant. We think that this is a really important attribute, particularly for patients with non-small cell lung cancer, where, say, 40% of patients will develop CNS metastases at some point in their treatment journey.

Mark LanasaChief Medical Officer for Solid Tumors

The top line numbers, we had a confirmed response rate of 38%, which is the highest that has been reported with this mechanism to date. We had progression-free survival of 8.1 months, which really compares favorably to currently available therapies in second line or later non-small cell lung cancer. Critically, we had an intracranial response rate of 30%, which was consistent with our systemic response rates. We are very excited about the opportunities that are before us in non-small cell lung cancer. It will be starting combinations with daraxonrasib through our RevMed collaboration in pancreatic cancer any day. From there, I would highlight our CDK4 selective molecule. The core hypothesis there is that by having greater selectivity for CDK4 over six, you can dial down the CDK6-related hematologic toxicities that are dose-limiting and have deeper, more consistent coverage of CDK4. We presented at ASCO this year a 70% response rate.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day